Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

STACIE: Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy

NCT05559164 is registered in ClinicalTrials.gov with Rutgers, The State University of New Jersey as lead sponsor.

NCT NCT05559164
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05559164 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
STACIE: Statins for Reduction of Cardiac Toxicity in Patients Receiving HER2 Targeted Therapy
Lead sponsor
Rutgers, The State University of New Jersey
Phase
Phase 2
Overall status
Recruiting
Start date
September 19, 2022
Completion date
March 1, 2027
Enrollment
60 (estimated)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

cardiac toxicity, early-stage breast cancer